Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.
Rider DA, Havenith CE, de Ridder R, Schuurman J, Favre C, Cooper JC, Walker S, Baadsgaard O, Marschner S, vandeWinkel JG, Cambier J, Parren PW, Alexander DR. Rider DA, et al. Among authors: vandewinkel jg. Cancer Res. 2007 Oct 15;67(20):9945-53. doi: 10.1158/0008-5472.CAN-07-1148. Cancer Res. 2007. PMID: 17942927 Clinical Trial.
In situ depletion of CD4+ T cells in human skin by Zanolimumab.
Villadsen LS, Skov L, Dam TN, Dagnaes-Hansen F, Rygaard J, Schuurman J, Parren PW, van de Winkel JG, Baadsgaard O. Villadsen LS, et al. Arch Dermatol Res. 2007 Feb;298(9):449-55. doi: 10.1007/s00403-006-0710-0. Epub 2006 Nov 8. Arch Dermatol Res. 2007. PMID: 17091277
Novel human antibody therapeutics: the age of the Umabs.
Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Ruuls SR, et al. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi: 10.1002/biot.200800110. Biotechnol J. 2008. PMID: 18702090 Free PMC article. Review.
An integrated science-based approach to drug development.
Parren PW, van de Winkel JG. Parren PW, et al. Curr Opin Immunol. 2008 Aug;20(4):426-30. doi: 10.1016/j.coi.2008.06.006. Epub 2008 Jul 9. Curr Opin Immunol. 2008. PMID: 18602995 No abstract available.
300 results